Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)

09.02.2023 - - Global collaboration includes ENTR-701, Entrada’s late-stage preclinical candidate for the treatment of DM1 - - Company’s cash runway extended into the second half of 2025 - BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. ... Seite 1

Related Keywords

Boston ,Massachusetts ,United States , ,Entrada Therapeutics Inc ,Nasdaq ,Escape Vehicle ,Antitrust Improvements Act ,